Tag: MaaT
MaaT Pharma presents positive data for MaaT013 at 18 months at EBMT 2024 showing a clear advantage in terms of overall survival in aGvHD in its compassionate access program – 04/15/2024 at 07:40
MaaT Pharma presents positive data for MaaT013 at 18 months at EBMT 2024 showing a clear advantage in terms of overall survival in aGvHD in its compassionate access program:• Positive…
MaaT Pharma Presents Promising Preclinical Data at AACR for MaaT034
By Alexandra Saintpierre Published on 04/08/2024 at 8:52 p.m. Photo credit © SunocciPictures (Boursier.com) — The biotechnology…
MaaT Pharma presents promising preclinical data at AACR for MaaT034 aimed at improving patient responses to immunotherapies – 04/08/2024 at 7:30 p.m.
MaaT Pharma Presents Promising Preclinical Data at AACR for MaaT034 Aimed to Improve Patient Responses to Immunotherapies Lyon, France, April 8, 2024, 7:20 p.m. CET – MaaT Pharma (EURONEXT: MAAT…
Maat Pharma: more reviews
(Boursier.com) — Maat Pharma climbs 3.5% to 9.25 euros this Friday, while Gilbert Dupont (Societe Generale Group) published a study entitled “Failure and MaaT”, with a purchase recommendation and a…
Maat Pharma: cash flow until the end of the 3rd quarter 2024
(Boursier.com) — The turnover of Maat Pharma is 2.2 ME for the financial year ending December 31, 2023. This is the highest turnover generated so far by the company. The…
MaaT Pharma publishes its annual results for the year 2023 and provides an update on its activities – 03/28/2024 at 6:15 p.m.
MaaT Pharma (EURONEXT: MAAT – the “Company”), an advanced clinical stage biotechnology company, leader in the development of Microbiome Ecosystem TherapiesTM (MET) aimed at improving the survival of cancer patients,…
MaaT Pharma strengthens its management team
(AOF) – MaaT Pharma, a late clinical stage biotechnology company, announces the appointment of Jonathan Chriqui, PharmD, to the position of chief business officer and member of the management team.…
MaaT Pharma: end of phase 2 trial recruitment – 03/05/2024 at 2:09 p.m.
(CercleFinance.com) – MaaT Pharma announced on Tuesday that it had completed the recruitment of patients in its Phase 2a clinical trial evaluating MaaT013, its most advanced drug candidate, in melanoma.…
MaaT Pharma: positive results in blood cancers
(CercleFinance.com) – MaaT Pharma shares rose on Monday on the Paris Stock Exchange following the presentation of positive results in blood cancers for its most advanced drug candidate. The Lyon…
Maat pharma: In acute graft-versus-host disease, MaaT Pharma announces promising results
(BFM Bourse) – The Lyon biotech announced positive results for MaaT013, its most advanced drug candidate at the annual conference of the American Society of Hematology. Two years after its…
MaaT Pharma presents positive results for MaaT013, its most advanced drug candidate, at ASH 2023 and details the ongoing Phase 2b trial evaluating MaaT033 – 11/12/2023 at 07:38
MaaT Pharma presents positive results for MaaT013, its most advanced drug candidate, at ASH 2023 and details the ongoing Phase 2b trial evaluating MaaT033 • Positive efficacy results from 111…
MaaT Pharma receives funding from the State
By Alexandra Saintpierre Published on 11/30/2023 at 10:16 p.m. Photo credit © Maat Pharma (Boursier.com) — The biotechnology…